Oaktree Capital Management has held the close of its Life Sciences Lending Fund – its first dedicated life sciences fund – and related vehicles, oversubscribed with total capital commitments in excess of $2.3 billion.
Oaktree Capital Management (Oaktree) has held the close of its Life Sciences Lending Fund – its first dedicated life sciences fund – and related vehicles, oversubscribed with total capital commitments in excess of $2.3 billion.
According to Oaktree, the fund aims to generate attractive risk-adjusted returns by providing bespoke capital solutions to “innovative companies across the life sciences sector globally, with a focus on high-growth sub-sectors, such as biopharma and medical devices.”
The fund focuses on lending to companies with specific attributes, including those with diverse product portfolios comprised of late-stage assets targeting difficult-to-treat medical conditions, strong intellectual property and/or state-of-the-art manufacturing facilities, which, along with careful structuring, provides for adequate risk protection.
The fund is led by co-portfolio managers Armen Panossian, Head of Performing Credit at Oaktree, who earned an MS in health services research from Stanford Medical School, as well as a JD and MBA from Harvard University, and Aman Kumar, Managing Director at Oaktree and a former NHS surgeon, who is a member of the Royal College of Surgeons of England and earned an MBA from the Wharton School. They are supported by a global team of sector-dedicated, experienced investment professionals and the resources of Oaktree’s broader credit platform.
